After 37 years and 10 albums, the New Zealand group are calling it quits — but not before one last all-out tour.

Investment analysts at National Bank Financial lifted their FY2024 earnings estimates for shares of EMX Royalty in a note issued to investors on Monday, February 10th. National Bank Financial analyst ...

Portfolio Receipts of $742 million in Q4 2024 and $2,801 million for FY 2024Royalty Receipts growth of 12% in Q4 2024 and 13% for FY 2024 Net cash provided by operating activities of $743 million in ...

We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at ...

Royalty Pharma to provide R&D investment of up to $250 million for Biogen's litifilimab, a potential first-in-class biologic in Phase 3 development for the treatment of lupus. NEW ...

NEW YORK (AP) — NEW YORK (AP) — Royalty Pharma (RPRX) on Tuesday reported fourth-quarter net income of $208 million. The New York-based company said it had net income of 35 cents per share. Earnings, ...

Discover new cryptocurrency releases that are causing a stir in the market. Stay ahead with these new and innovative digital assets.

Watch on as Kaitlynn gives us the grand tour of Kikko's new lounge. She created climbing spaces for her furry feline. There's ...

Sabine Royalty Trust offers a high-yield, inflation-hedged investment with steady royalty income and minimal operational ...

Royalty Pharma is giving Biogen $250 million for its lupus treatment litifilimab, which is currently in Phase 3 development ...